Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Sees Significant Growth in Short Interest

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) saw a significant increase in short interest during the month of December. As of December 31st, there was short interest totalling 4,820,000 shares, an increase of 8.6% from the December 15th total of 4,440,000 shares. Based on an average daily volume of 400,900 shares, the days-to-cover ratio is currently 12.0 days. Approximately 19.6% of the company’s shares are short sold.

Analyst Ratings Changes

Several research analysts have commented on the company. HC Wainwright reaffirmed a “buy” rating and set a $63.00 target price on shares of Arcturus Therapeutics in a report on Monday, January 13th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcturus Therapeutics in a research note on Monday, December 16th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $66.75.

Arcturus Therapeutics Trading Down 1.3 %

Shares of Arcturus Therapeutics stock opened at $16.79 on Monday. The company has a market cap of $454.79 million, a P/E ratio of -7.56 and a beta of 2.63. The business has a 50-day moving average price of $17.46 and a two-hundred day moving average price of $19.83. Arcturus Therapeutics has a 1-year low of $14.30 and a 1-year high of $45.00.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its earnings results on Thursday, November 7th. The biotechnology company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.44. The business had revenue of $41.67 million during the quarter, compared to the consensus estimate of $49.16 million. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. During the same period in the previous year, the company posted ($0.61) earnings per share. Equities research analysts forecast that Arcturus Therapeutics will post -2.31 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of ARCT. XTX Topco Ltd acquired a new position in shares of Arcturus Therapeutics during the second quarter valued at about $596,000. Point72 DIFC Ltd bought a new position in Arcturus Therapeutics in the second quarter worth approximately $188,000. Squarepoint Ops LLC acquired a new stake in Arcturus Therapeutics in the second quarter valued at approximately $718,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Arcturus Therapeutics during the second quarter valued at approximately $142,000. Finally, Deerfield Management Company L.P. Series C acquired a new position in shares of Arcturus Therapeutics during the second quarter worth approximately $958,000. 94.54% of the stock is owned by institutional investors.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.